DK1490391T3 - 11beta long chain substituted 19-nor-17alpha-pregna-1,3,5 (10) -triene-17beta-ols with a 21.2alpha-lactone ring - Google Patents

11beta long chain substituted 19-nor-17alpha-pregna-1,3,5 (10) -triene-17beta-ols with a 21.2alpha-lactone ring

Info

Publication number
DK1490391T3
DK1490391T3 DK03717244T DK03717244T DK1490391T3 DK 1490391 T3 DK1490391 T3 DK 1490391T3 DK 03717244 T DK03717244 T DK 03717244T DK 03717244 T DK03717244 T DK 03717244T DK 1490391 T3 DK1490391 T3 DK 1490391T3
Authority
DK
Denmark
Prior art keywords
pregna
ols
long chain
lactone ring
11beta
Prior art date
Application number
DK03717244T
Other languages
Danish (da)
Inventor
Gerd Mueller
Alexander Hillisch
Jens Hoffmann
Karl-Heinrich Fritzemeier
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1490391T3 publication Critical patent/DK1490391T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention relates to novel 19-nor-17 alpha -pregna-1,3,5(10)-trien-17 beta -ols with a 21,16 alpha lactone ring and a long chain substituent in the 11 beta position of general formula (II) where R<11> is a 6 to 17 C straight chain alkyl group and R<3> and R<13> have the meanings more closely given in the description. The compounds have a tissue-selective pure anti-oestrogen effect and are thus suitable for the production of medicaments.
DK03717244T 2002-03-27 2003-03-27 11beta long chain substituted 19-nor-17alpha-pregna-1,3,5 (10) -triene-17beta-ols with a 21.2alpha-lactone ring DK1490391T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10214180A DE10214180A1 (en) 2002-03-27 2002-03-27 11beta-lankgettig-substituted 19-nor-17alpha-pregna-1,3,5 (10) -triene-17beta-ols with a 21,16alpha lactone ring

Publications (1)

Publication Number Publication Date
DK1490391T3 true DK1490391T3 (en) 2006-04-18

Family

ID=28050972

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03717244T DK1490391T3 (en) 2002-03-27 2003-03-27 11beta long chain substituted 19-nor-17alpha-pregna-1,3,5 (10) -triene-17beta-ols with a 21.2alpha-lactone ring

Country Status (8)

Country Link
EP (1) EP1490391B1 (en)
JP (1) JP2005526805A (en)
AT (1) ATE313552T1 (en)
AU (1) AU2003221528A1 (en)
DE (2) DE10214180A1 (en)
DK (1) DK1490391T3 (en)
ES (1) ES2254924T3 (en)
WO (1) WO2003080641A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1255659B (en) * 1961-05-31 1967-12-07 Abbott Lab Process for the manufacture of steroid lactones
US3089874A (en) * 1961-05-31 1963-05-14 Abbott Lab Steroid lactones
US3920634A (en) * 1974-08-30 1975-11-18 Lilly Co Eli 2,3-Dihydroestra-1,3,5(10)-trieno (16{60 ,17{60 -{62 ) furan-17{62 ols
DE10048634A1 (en) * 2000-09-27 2002-04-18 Jenapharm Gmbh 19-Nor-17alpha-pregna-1,3,5 (10) -trien-17beta-ole with a 21, 16alpha lactone ring

Also Published As

Publication number Publication date
ES2254924T3 (en) 2006-06-16
JP2005526805A (en) 2005-09-08
EP1490391A1 (en) 2004-12-29
DE10214180A1 (en) 2003-10-16
ATE313552T1 (en) 2006-01-15
AU2003221528A1 (en) 2003-10-08
EP1490391B1 (en) 2005-12-21
WO2003080641A1 (en) 2003-10-02
DE50302000D1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
DE602004008098D1 (en) SUBSTITUTED 2H-Ä1,2,4ÜTRIAZOLOÄ4,3-AÜPYRAZINE AS GSK-3 INHIBITORS
DK1485359T3 (en) sodium
CY1111693T1 (en) ANTIQUE FACTORS
DE69830504D1 (en) ANTITROMOMBOTIC MEANS
HN2003000348A (en) BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND VIRAL INFECTION OF HEPATITIS C AND ASSOCIATED ILLNESSES.
CY1107634T1 (en) PHARMACEUTICAL COMPOSITION
AP2002002637A0 (en) Novel piperazine
DK1585739T3 (en) Substituted arylcyclopropylacetamides as glucokinase activators
DE69919212D1 (en) AROMATIC AMIDES
CR7743A (en) NEW OXAZOL AND TIAZOL COMPOUNDS AS INHIBITOR OF THE TRANSFORMING GROWTH FACTOR (TGF)
SE0302116D0 (en) Novel compounds
TR200402454T4 (en) C-4 carbonate taxanes.
DE69923965D1 (en) ECTEINASCIDINDERIVATE
MA27610A1 (en) ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF BETA-AMYLOID PEPTIDE
ATE280767T1 (en) ANTIDIABETIC THIAZOLIDINDIONES AND THEIR PRODUCTION
DE60114640D1 (en) Antithrombosemittel
BRPI0416678A (en) pyrazolpyrimidines
GB0212410D0 (en) Organic compounds
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
MY125378A (en) Pentacyclic taxan compound
DK1490391T3 (en) 11beta long chain substituted 19-nor-17alpha-pregna-1,3,5 (10) -triene-17beta-ols with a 21.2alpha-lactone ring
EA200000261A3 (en) New substituted dimeric compounds, a process for their preparation and pharmaceutical compositions containing them
ATE342906T1 (en) TUMOR-INHIBITING CERAMIC COMPOUNDS
BRPI0410056A (en) imidazopyridine intermediates
IT1302289B1 (en) PHARMACEUTICAL COMPOSITIONS WITH ANTINEOPLASTIC ACTIVITY